134
Participants
Start Date
December 13, 2017
Primary Completion Date
March 23, 2023
Study Completion Date
March 23, 2023
ABvac40
ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminum hydroxide as adjuvant.
Placebo
Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminum hydroxide) without the conjugate.
Hospital Universitario Donosti, Donostia / San Sebastian
Hôpital François Mitterrand, Dijon
San Giovanni di Dio - Fatebenefratelli, Brescia
Hospital Santa Maria de Lleida, Lleida
Hospital San Pedro, Logroño
Complejo Hospitalario Ruber Juan Bravo, Madrid
Hospital Universitario 12 Octubre, Madrid
Hospital Ramón y Cajal, Colmenar Viejo
Hospital Clínico San Carlos, Madrid
CUN - Clínica Universidad de Navarra, Pamplona
Centre de Recherche Clinique du Gérontopôle, Toulouse
CHU de Montpellier, Montpellier
Cae Oroitu, Algorta
Hospital Clínico Universitario Lozano Blesa, Zaragoza
Hospital Mútua de Terrasa, Terrassa
Hospital General Universitario de Alicante, Alicante
Barcelona Beta Brain Research Center (BBRC), Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Fundació ACE, Barcelona
Hospital Vall d'Hebron, Barcelona
Hospital del Mar, Barcelona
Hospital U. de Burgos, Burgos
Karolinska Universitetssjukhuset, Stockholm
Lead Sponsor
Araclon Biotech S.L.
INDUSTRY